

Laura Patrussi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7919529/publications.pdf>

Version: 2024-02-01

46
papers

1,635
citations

361045

20
h-index

288905

40
g-index

55
all docs

55
docs citations

55
times ranked

2038
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | The <i>Helicobacter pylori</i> Vacuolating Toxin Inhibits T Cell Activation by Two Independent Mechanisms. <i>Journal of Experimental Medicine</i> , 2003, 198, 1887-1897. | 4.2 | 274 |
| 2 | Simvastatin inhibits T cell activation by selectively impairing the function of Ras superfamily GTPases. <i>FASEB Journal</i> , 2005, 19, 1-24. | 0.2 | 128 |
| 3 | p66SHC Promotes Apoptosis and Antagonizes Mitogenic Signaling in T Cells. <i>Molecular and Cellular Biology</i> , 2004, 24, 1747-1757. | 1.1 | 124 |
| 4 | Immune synapse targeting of specific recycling receptors by the intraflagellar transport system. <i>Journal of Cell Science</i> , 2014, 127, 1924-37. | 1.2 | 91 |
| 5 | F-actin dynamics control segregation of the TCR signaling cascade to clustered lipid rafts. <i>European Journal of Immunology</i> , 2002, 32, 435-446. | 1.6 | 83 |
| 6 | Simvastatin inhibits the MHC class II pathway of antigen presentation by impairing Ras superfamily GTPases. <i>European Journal of Immunology</i> , 2006, 36, 2885-2893. | 1.6 | 77 |
| 7 | Anthrax toxins inhibit immune cell chemotaxis by perturbing chemokine receptor signalling. <i>Cellular Microbiology</i> , 2007, 9, 924-929. | 1.1 | 68 |
| 8 | Defective Vav expression and impaired F-actin reorganization in a subset of patients with common variable immunodeficiency characterized by T-cell defects. <i>Blood</i> , 2005, 106, 626-634. | 0.6 | 59 |
| 9 | The small GTPase Rab8 interacts with VAMP-3 to regulate the delivery of recycling TCRs to the immune synapse. <i>Journal of Cell Science</i> , 2015, 128, 2541-52. | 1.2 | 59 |
| 10 | The small GTPase Rab29 is a common regulator of immune synapse assembly and ciliogenesis. <i>Cell Death and Differentiation</i> , 2015, 22, 1687-1699. | 5.0 | 57 |
| 11 | p52Shc is required for CXCR4-dependent signaling and chemotaxis in T cells. <i>Blood</i> , 2007, 110, 1730-1738. | 0.6 | 55 |
| 12 | Intracellular mediators of CXCR4-dependent signaling in T cells. <i>Immunology Letters</i> , 2008, 115, 75-82. | 1.1 | 54 |
| 13 | S1P1 expression is controlled by the pro-oxidant activity of p66Shc and is impaired in B-CLL patients with unfavorable prognosis. <i>Blood</i> , 2012, 120, 4391-4399. | 0.6 | 50 |
| 14 | SAP-Mediated Inhibition of Diacylglycerol Kinase δ Regulates TCR-Induced Diacylglycerol Signaling. <i>Journal of Immunology</i> , 2011, 187, 5941-5951. | 0.4 | 43 |
| 15 | Enhanced Chemokine Receptor Recycling and Impaired S1P1 Expression Promote Leukemic Cell Infiltration of Lymph Nodes in Chronic Lymphocytic Leukemia. <i>Cancer Research</i> , 2015, 75, 4153-4163. | 0.4 | 41 |
| 16 | Inhibition of diacylglycerol kinase δ restores restimulation-induced cell death and reduces immunopathology in XLP-1. <i>Science Translational Medicine</i> , 2016, 8, 321ra7. | 5.8 | 41 |
| 17 | The <i>Bordetella pertussis</i> adenylate cyclase toxin binds to T cells via LFA-1 and induces its disengagement from the immune synapse. <i>Journal of Experimental Medicine</i> , 2011, 208, 1317-1330. | 4.2 | 38 |
| 18 | The CXCL12/CXCR4 Axis as a Therapeutic Target in Cancer and HIV-1 Infection. <i>Current Medicinal Chemistry</i> , 2011, 18, 497-512. | 1.2 | 37 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Cooperation and selectivity of the two Grb2 binding sites of p52Shc in T-cell antigen receptor signaling to Ras family GTPases and Myc-dependent survival. <i>Oncogene</i> , 2005, 24, 2218-2228. | 2.6 | 29 |
| 20 | p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from I ² -arrestin at early endosomes. <i>Oncogene</i> , 2018, 37, 1534-1550. | 2.6 | 23 |
| 21 | Negative regulation of chemokine receptor signaling and B-cell chemotaxis by p66Shc. <i>Cell Death and Disease</i> , 2014, 5, e1068-e1068. | 2.7 | 21 |
| 22 | Expression of the p66Shc protein adaptor is regulated by the activator of transcription STAT4 in normal and chronic lymphocytic leukemia B cells. <i>Oncotarget</i> , 2016, 7, 57086-57098. | 0.8 | 19 |
| 23 | The Glycerophosphoinositols: From Lipid Metabolites to Modulators of T-Cell Signaling. <i>Frontiers in Immunology</i> , 2013, 4, 213. | 2.2 | 18 |
| 24 | Nonsteroidal anti-inflammatory drugs inhibit a Fyn-dependent pathway coupled to Rac and stress kinase activation in TCR signaling. <i>Blood</i> , 2005, 105, 2042-2048. | 0.6 | 17 |
| 25 | p66Shc deficiency in the E ^{1/4} -TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape. <i>Haematologica</i> , 2019, 104, 2040-2052. | 1.7 | 17 |
| 26 | Glycerophosphoinositol-4-phosphate enhances SDF-1 α -stimulated T-cell chemotaxis through PTK-dependent activation of Vav. <i>Cellular Signalling</i> , 2007, 19, 2351-2360. | 1.7 | 12 |
| 27 | Azetidin-2-one-based small molecules as dual hHDAC6/HDAC8 inhibitors: Investigation of their mechanism of action and impact of dual inhibition profile on cell viability. <i>European Journal of Medicinal Chemistry</i> , 2022, 238, 114409. | 2.6 | 11 |
| 28 | p66Shc-dependent apoptosis requires Lck and CamKII activity. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2012, 17, 174-186. | 2.2 | 9 |
| 29 | P66Shc: A Pleiotropic Regulator of B Cell Trafficking and a Gatekeeper in Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2020, 12, 1006. | 1.7 | 9 |
| 30 | Optimization of Organotypic Cultures of Mouse Spleen for Staining and Functional Assays. <i>Frontiers in Immunology</i> , 2020, 11, 471. | 2.2 | 9 |
| 31 | Nature vs. Nurture: The Two Opposing Behaviors of Cytotoxic T Lymphocytes in the Tumor Microenvironment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11221. | 1.8 | 9 |
| 32 | Abnormalities in chemokine receptor recycling in chronic lymphocytic leukemia. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 3249-3261. | 2.4 | 8 |
| 33 | LMW-PTP targeting potentiates the effects of drugs used in chronic lymphocytic leukemia therapy. <i>Cancer Cell International</i> , 2019, 19, 67. | 1.8 | 7 |
| 34 | Enhanced IL-9 secretion by p66Shc-deficient CLL cells modulates the chemokine landscape of the stromal microenvironment. <i>Blood</i> , 2021, 137, 2182-2195. | 0.6 | 7 |
| 35 | Positive and negative regulators of Ras in T cells. <i>Signal Transduction</i> , 2004, 4, 9-16. | 0.7 | 6 |
| 36 | Interleukin (IL)-9 Supports the Tumor-Promoting Environment of Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2021, 13, 6301. | 1.7 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | The Rab GTPase Rab8 as a shared regulator of ciliogenesis and immune synapse assembly: From a conserved pathway to diverse cellular structures. <i>Small GTPases</i> , 2016, 7, 16-20. | 0.7 | 5 |
| 38 | Analysis of TCR/CD3 Recycling at the Immune Synapse. <i>Methods in Molecular Biology</i> , 2017, 1584, 143-155. | 0.4 | 5 |
| 39 | p66Shc Deficiency in Chronic Lymphocytic Leukemia Promotes Chemokine Receptor Expression Through the ROS-Dependent Inhibition of NF- κ B. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 5 |
| 40 | Glycerophosphoinositol Promotes Apoptosis of Chronic Lymphocytic Leukemia Cells by Enhancing Bax Expression and Activation. <i>Frontiers in Oncology</i> , 2022, 12, 835290. | 1.3 | 2 |
| 41 | Themis releases the brakes on TCR signaling during thymocyte selection by disabling SHP-1. <i>Cellular and Molecular Immunology</i> , 2017, 14, 724-726. | 4.8 | 1 |
| 42 | Dysfunctional Immune Synapses in T Cell Immunodeficiencies. <i>Rare Diseases of the Immune System</i> , 2021, , 43-63. | 0.1 | 1 |
| 43 | The Bordetella pertussis adenylate cyclase toxin binds to T cells via LFA-1 and induces its disengagement from the immune synapse. <i>Journal of Cell Biology</i> , 2011, 193, i12-i12. | 2.3 | 0 |
| 44 | Boosting chemokine receptor recycling: an elixir of life for chronic lymphocytic leukemia. <i>Oncotarget</i> , 2018, 9, 33444-33445. | 0.8 | 0 |
| 45 | The B-Side of the Immune Response. <i>Rare Diseases of the Immune System</i> , 2019, , 1-20. | 0.1 | 0 |
| 46 | Mucosal B Cells. <i>Rare Diseases of the Immune System</i> , 2019, , 21-34. | 0.1 | 0 |